论文部分内容阅读
虽然关于药物经济学(PE)/卫生经济(HE)的研究数量不断上升,但对于决策制定者对其应用的情况还知之甚少。研究结果是否被使用了?如果使用了,那么他们对于决策的制定有没有影响?虽然PE/HE研究可以只为满足学术兴趣而实施,但其主要目的应是用于帮助那些制定医疗保健资源分配的决策者们。因此,ISPOR工作组关于在医疗保健决策制定中PE/HE使用的研究就是为了保证好的PE/HE研究实践应关注卫生保健决策制定者的需要,并为想了解及应用PE/HE研究结果的卫生保健决策制定者们建立一个“工具箱”。此报道的结构如下:首先,讨论医疗保健决策制定与使用PE/HE研究之间的关系。第二,略述小组的工作方法。第三,回顾现今关于决策制定者对于PE/HE研究态度的著作。第四,对PE/HE研究报告中好的习惯做法要素进行说明。最后,略述今后研究的几个问题。
Although the number of studies on pharmacoeconomics (PE) / health economy (HE) is on the rise, little is known about how policymakers have applied them. Are the findings used? If so, do they have any impact on decision-making? Although PE / HE research can be conducted solely to satisfy academic interests, its main purpose should be to help those who design health care resource allocations The decision makers. Therefore, the ISPOR Working Group’s study on the use of PE / HE in healthcare decision-making is designed to ensure that good PE / HE research practices focus on the needs of health-care decision makers and that in order to understand and apply PE / HE research findings Health care decision makers create a “toolbox.” The structure of this report is as follows: First, discuss the relationship between health care decision-making and the use of PE / HE research. Second, outlining the group’s working methods. Third, review the current literature on decision-makers’ attitudes toward PE / HE. Fourth, explain the elements of good practices in PE / HE research reports. Finally, a few questions about future research are outlined.